Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
PCVX
#961
Vaxcyte, Inc. Common Stock
62.760
0
USD
+1.64%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+1.64%
Changement Mensuel
+13.92%
Evolution sur 6 mois
+48.37%
Changement Annuel
+48.37%
Clôture Précédente
61.750
0
Open
62.760
0
Bid
Ask
Low
62.760
0
High
62.760
0
Volume
108
Marchés
Actions des Marchés US
Soins de Santé
PCVX
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
51.33 M
56.31 M
80.03 M
108.41 M
128.76 M
143.92 M
—
Valuation ratios
Enterprise value
977.58 M
1.27 B
2.94 B
6.43 B
10.15 B
6.47 B
19.34 B
Price to earnings ratio
—
—
-13.72
-15.2
-21.54
-8.2
-33.01
Price to sales ratio
—
—
-2 022.62
-3 223.57
-2 282.67
—
—
Price to cash flow ratio
—
—
-17.95
-20.6
-22.06
-9.58
-37.94
Price to book ratio
—
—
3.21
4.93
3.02
2.34
3.44
Enterprise value to EBITDA ratio
-10.8
-12.68
-12.73
-13.77
-17.91
—
—
Profitability ratios
Return on assets %
-0.23
-0.31
-0.22
-0.29
-0.13
-0.26
-0.24
Return on equity %
-0.26
-0.35
-0.23
-0.32
-0.14
-0.29
-0.26
Return on invested capital %
-2 091.55
-843.77
—
-810.68
-210.08
-226.32
-227.97
Gross margin %
100
100
100
100
100
—
—
Operating margin %
3 810.34
-6 211.5
15.34 K
24.67 K
13.02 K
—
—
EBITDA margin %
3 850.57
-6 003.65
15.27 K
24.61 K
12.96 K
—
—
Net margin %
3 794.85
-5 996.23
14.76 K
21.21 K
10.6 K
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
8.3
8.93
23.26
7.54
12.75
7.91
45.55
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
-0.01
0
-0
-0
-0
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
-2.63
-3.05
-3.71
-4.82
-4.82
EBIT per share
—
—
-3.6
-4.84
-4.7
—
—
EBITDA per share
—
—
-3.56
-4.8
-4.65
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
14.36
11.12
14.32
11.47
48.57
Net current asset value per share
—
—
14.53
11.28
14.66
11.96
50.2
Tangible book value per share
—
—
14.7
12.77
27.1
19.73
87.13
Working capital per share
—
—
13.9
9.78
13.51
10.45
45.37
Book value per share
—
—
14.7
12.77
27.1
19.73
87.13
Nouvelles
Vera Therapeutics nomme Jane Wright-Mitchell directrice juridique
Vaxcyte termine le recrutement de deux essais de Phase 3 pour le VAX-31
Vaxcyte publie les résultats de l’étude de phase 1/2 du VAX-31 dans Lancet
La directrice financière de Vaxcyte vend pour 105.000$ d’actions
Jefferies réitère sa recommandation d’achat sur Vaxcyte après des clarifications réglementaires
Jefferies reiterates Vaxcyte stock Buy rating on regulatory clarity
BTIG relève l’objectif de cours de Vaxcyte à 89$ sur l’avantage de couverture du vaccin
BTIG raises Vaxcyte price target to $89 on vaccine breadth edge
Leerink relève l’objectif de cours de Vaxcyte suite à l’expansion du pipeline de vaccins
Leerink raises Vaxcyte stock price target on vaccine pipeline expansion
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Ovintiv to Report Q4 Earnings: What's in Store for the Stock?